Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KPTI | Common Stock | Award | $0 | +21K | +3% | $0.00 | 720K | Feb 28, 2022 | Direct | F1 |
transaction | KPTI | Common Stock | Sale | -$63.7K | -6.23K | -0.86% | $10.24 | 714K | Feb 28, 2022 | Direct | F2, F3 |
transaction | KPTI | Common Stock | Sale | -$63.7K | -6.23K | -0.69% | $10.24 | 898K | Feb 28, 2022 | By Spouse | F3, F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KPTI | Stock Option (right to buy) | Award | $0 | +27K | $0.00 | 27K | Feb 28, 2022 | Common Stock | 27K | $10.33 | Direct | F5 |
Id | Content |
---|---|
F1 | Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. |
F2 | This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. |
F3 | Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
F4 | This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. |
F5 | This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |